All Videos

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.

Strong mentorship provides resilience for young clinicians navigating evolving challenges in practice.

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.

Panelists discuss how roflumilast foam, though newly approved for scalp psoriasis, is already showing promise off-label for conditions such as seborrheic dermatitis and nail psoriasis, thanks to its well-tolerated, alcohol- and propylene glycol–free vehicle that improves patient comfort, adherence, and expands topical options for difficult-to-treat areas—potentially reducing reliance on systemic therapies.

At DERM 2025, David Cotter, MD, PhD, shared how GEP testing revolutionizes skin cancer management and enhances patient care at the forefront of dermatology innovation.

An expert discusses the preference for narrow-spectrum oral antibiotics in acne treatment due to their favorable safety profile, emphasizing a short-term, combination approach aligned with stewardship principles and the need to balance clinical effectiveness, patient preferences, and access challenges.

An expert discusses the importance of setting clear treatment timelines and goals for oral antibiotics in acne, emphasizing a short-term, combination approach with topicals, careful antibiotic selection based on adverse effects and spectrum, and the benefits of narrow-spectrum agents to support stewardship and patient adherence.

At the Elevate-Derm Summer 2025 meeting, Walter Liszewksi, MD, discussed how new topical therapies, particularly JAK inhibitors, are transforming AD care with rapid itch relief, effectiveness in complex cases, and patient-friendly formulations for sensitive areas.

Dr. Rossi DERM MD blends dermatologic science with K-beauty aesthetics for effective, evidence-based solutions.

Discover Anthony Rossi, MD, FAAD, FACMS's innovative skin care line targeting inflammatory aging with clinical science, clean formulations, and effective anti-aging solutions.

A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

Panelists discuss how the recent FDA approval of roflumilast foam for scalp psoriasis represents a significant advancement, combining strong efficacy with a gentle, moisturizing vehicle that enhances tolerability and adherence across diverse hair types and skin tones while offering a steroid-sparing option free from common adverse effects such as hypopigmentation.

An expert discusses how the primary effectiveness of oral antibiotics in acne lies in their anti-inflammatory properties—especially those of tetracyclines—highlighting their broader immunomodulatory benefits and the importance of patient education to support informed, science-based treatment decisions.

An expert discusses how clinical presentation guides the selective use of oral antibiotics for moderate acne, emphasizing short-term treatment, careful transitions to maintenance therapy, and individualized plans to achieve lasting skin clearance while minimizing antibiotic exposure.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.

Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.

An expert discusses how barzolvolimab's unique mast cell-targeting mechanism, rapid efficacy, and potential disease-modifying effects position it as a promising treatment option for CSU patients who fail antihistamines or omalizumab therapy.

An expert discusses how barzolvolimab's safety profile includes manageable adverse events such as minimal and reversible hair color changes, mild neutropenia, and skin hyperpigmentation that are not clinically concerning.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

Panelists discuss how safety and tolerability are key advantages of newer topical psoriasis treatments such as tapinarof and roflumilast, which avoid many steroid-related risks such as hypothalamic-pituitary-adrenal (HPA) axis suppression and skin thinning, cause minimal irritation, and have favorable real-world profiles that support their use as effective, long-term, steroid-sparing therapies.

An expert discusses how successful psoriasis management requires patient-centered care, shared decision-making, matching therapy to individual patient needs rather than just the disease, and ongoing communication to ensure treatment adherence and success.

An expert discusses how treating busy professionals with scalp and nail psoriasis involves addressing injection anxiety, treatment adherence challenges, and the emotional impact of visible disease through health care provider–administered biologics.

An expert how managing psoriasis in active travelers requires considering dosing frequency, insurance transitions from commercial to Medicare coverage, and selecting biologics with longer intervals between treatments.

An expert discusses how treating older patients with psoriasis, such as a 72-year-old retired teacher, requires addressing cognitive decline, dexterity issues, and comorbidities by considering in-office biologic administration and buy-and-bill processes for Medicare accessibility.

An expert discusses how updated guidelines, patient preferences, and insurance access shape responsible oral antibiotic use in acne care, highlighting the importance of stewardship, shared decision-making, and equitable treatment access.

An expert discusses the shift in acne treatment from broad-spectrum antibiotics to targeted and nonantibiotic therapies, emphasizing microbiome preservation, resistance reduction, and personalized patient care.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.